To evaluate the effect of therapy intensification by means of an integrase inhibitor with or without CCR5 inhibitor treatment on the lymphoid reservoir in patients chronically infected with HIV-1, successfully treated with "conventional triple therapy", measured by:

Pregnancy - breast-feeding ( a pregnancy test will be done at the inclusion visit)

Co-infection with HIV-2

History of immunomodulator treatment (interleukin-2, alpha-interferon)

Ongoing treatment of HBV or HCV co-infection

Blood constitution disorders

Contraindications to the administration of raltegravir or maraviroc

Circulating CD4 nadir <100/mm3 in the natural history of HIV-1 infection.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00935480